STAT3 and ovarian carcinoma: Suppresses ovarian cancer cell proliferation and macrophage-induced protumor effects by inhibiting STAT3; reduces IL-10 and other M2 markers in macrophages; enhances sensitivity to chemotherapy drugs (e.g., CDDP, PTX) in cancer cells.